Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO

To demonstrate in patients with T2DM and dyslipidemia not appropriately controlled with a statin and receiving metformin, the superiority of a fixed combination of fenofibrate and metformin vs metform...

Lead sponsor: Solvay Pharmaceuticals•70 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDPhase 3

Acceptability of a Fixed Combination of Fenofibrate and Metformin

NCT00348725 · Dyslipidemia/Glucose Metabolism Disorder

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 16, 2010Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment482

Start dateOct 2006

Last updatedApr 16, 2010

Condition

Dyslipidemia/Glucose Metabolism Disorder

Locations shown

C LF23-0121 06 01 Site107

Brno

C LF23-0121 06 01 Site108

Holešov

C LF23-0121 06 01 Site101

Karlovy Vary

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2010Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions